ALUR vs. KRMD, BLUA, BWAY, TELA, STIM, NVNO, SEPA, PDEX, SRTS, and MGRM
Should you be buying Allurion Technologies stock or one of its competitors? The main competitors of Allurion Technologies include KORU Medical Systems (KRMD), BlueRiver Acquisition (BLUA), BrainsWay (BWAY), TELA Bio (TELA), Neuronetics (STIM), enVVeno Medical (NVNO), SEP Acquisition (SEPA), Pro-Dex (PDEX), Sensus Healthcare (SRTS), and Monogram Orthopaedics (MGRM). These companies are all part of the "surgical & medical instruments" industry.
KORU Medical Systems (NASDAQ:KRMD) and Allurion Technologies (NYSE:ALUR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, community ranking, valuation and profitability.
KORU Medical Systems has higher earnings, but lower revenue than Allurion Technologies. KORU Medical Systems is trading at a lower price-to-earnings ratio than Allurion Technologies, indicating that it is currently the more affordable of the two stocks.
KORU Medical Systems received 33 more outperform votes than Allurion Technologies when rated by MarketBeat users. However, 100.00% of users gave Allurion Technologies an outperform vote while only 60.00% of users gave KORU Medical Systems an outperform vote.
In the previous week, Allurion Technologies had 14 more articles in the media than KORU Medical Systems. MarketBeat recorded 15 mentions for Allurion Technologies and 1 mentions for KORU Medical Systems. Allurion Technologies' average media sentiment score of 1.94 beat KORU Medical Systems' score of 0.45 indicating that KORU Medical Systems is being referred to more favorably in the media.
KORU Medical Systems has a beta of 0.55, indicating that its stock price is 45% less volatile than the S&P 500. Comparatively, Allurion Technologies has a beta of -0.13, indicating that its stock price is 113% less volatile than the S&P 500.
KORU Medical Systems presently has a consensus target price of $3.50, suggesting a potential upside of 53.51%. Allurion Technologies has a consensus target price of $5.00, suggesting a potential upside of 190.70%. Given KORU Medical Systems' higher probable upside, analysts plainly believe Allurion Technologies is more favorable than KORU Medical Systems.
KORU Medical Systems has a net margin of -45.24% compared to KORU Medical Systems' net margin of -117.30%. KORU Medical Systems' return on equity of 0.00% beat Allurion Technologies' return on equity.
58.6% of KORU Medical Systems shares are owned by institutional investors. Comparatively, 21.4% of Allurion Technologies shares are owned by institutional investors. 21.7% of KORU Medical Systems shares are owned by company insiders. Comparatively, 20.0% of Allurion Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Summary
KORU Medical Systems beats Allurion Technologies on 11 of the 17 factors compared between the two stocks.
Get Allurion Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALUR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Allurion Technologies Competitors List
Related Companies and Tools